In the present study, we have retrospectively studied all CMV-mismatched renal transplant patients at Uppsala University Hospital over a 10-year period
Background and Objective: Acyclovir is primarily cleared by the kidneys
5 g/day if the clearance was between 25 and 50 ml, and continued for 3 months
Because GCV has a more potent inhibitory effect on CMV than does ACV, intravenous GCV is the first
The amount of acyclovir that induces ARF is usually more than 1000 mg/d for adults
High-dose extended interval ("once-daily"): patients with normal renal function who are not morbidly obese or fluid overloaded
5 mg/kg IV q8h
With intravenous use: Use normal intravenous dose every 12 hours if eGFR 25–50 mL/minute/1
A recently completed multi center case-control study assessed the impact of immunosuppressive therapy on PTLD risk among renal transplant patients and collected information on the use of anti-viral therapy
DOSE IN RENAL IMPAIRMENT GFR (mL/MIN) 25–50 Dose as in normal renal function 10–25 Simplex: 200 mg 3–4 times daily
This article provides guidelines for vaccination in this population, based on the latest evidence and expert consensus
7 cases/1,000 PY) and LuTx (38
This is the value of acyclovir clearance in people with anuria and is the basis of acyclovir dose Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R
Dosage adjustment is recommended when administering acyclovir to patients with renal impairment (See DOSAGE AND ADMINISTRATION)
i
All This phase III study is aiming to enroll 600 kidney transplant recipients, who will be randomized equally in a double blinded manner in two arms: one arm will receive letermovir, acyclovir and placebo and the other arm will receive valganciclovir and two placebos (to letermovir and acyclovir)